Searchlight Pharma
By therapeutic area
| Therapeutic area | Premium | Deals |
|---|---|---|
| dermatology | ×0.70 | 3 |
By stage at signing
| Phase | Premium | Deals |
|---|---|---|
| approved | ×0.70 | 3 |
Strategy profile
Based on 4 disclosed transactions, Searchlight Pharma concentrates its licensing activity in Dermatology, Other. Searchlight Pharma pays a 0.70x discount to market median, with the strongest premiums in Dermatology (0.70x). Their most common deal structure is License, with an average disclosed value of $13M. Most recent activity: 2023.
Premium by therapeutic area
How Searchlight Pharma pays relative to peer medians in each TA
Pipeline coverage & gaps
Searchlight Pharma has disclosed activity in 1 of 12 tracked therapeutic areas. Gaps may represent whitespace opportunities for licensors.
Deal type breakdown
How this buyer structures its transactions
| Deal type | Count | Avg upfront | Avg total value |
|---|---|---|---|
| LicensePrimary | 4 | $500,000 | $13M |
Recent disclosed deals
| Year | Asset | Licensor | Indication | Phase | Upfront | Total |
|---|---|---|---|---|---|---|
| 2023 | DONESTA | Mithra Pharmaceuticals | symptoms of menopause (vasomotor symptoms) | phase_3 | — | $18M |
| 2023 | TWYNEO and EPSOLAY | Sol-Gel Technologies | acne vulgaris | approved | — | $11M |
| 2023 | TWYNEO and EPSOLAY | Sol-Gel Technologies, Ltd. | acne vulgaris and rosacea | approved | $500,000 | $11M |
| 2023 | TWYNEO and EPSOLAY | Sol-Gel Technologies | acne vulgaris and rosacea | approved | — | $11M |
How this is computed
For each Searchlight Pharma deal we find the median total deal value of comparable transactions (same therapeutic area + phase, falling back to TA-only with ≥3 peers). The buyer’s deal divided by the peer median is the per-deal premium. We trim outliers, take the trimmed mean, and clamp to [0.7×, 1.5×] to reject data errors. Confidence scales with sample size.
Trimmed mean of 3 disclosed deal premiums vs. peer medians. Raw premium 0.387, clamped to [0.7, 1.5].